Skip Navigation


Rheumatology Advance Access originally published online on July 25, 2008
Rheumatology 2008 47(9):1439-1440; doi:10.1093/rheumatology/ken297
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/9/1439    most recent
ken297v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Perricone, R.
Right arrow Articles by Perricone, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Perricone, R.
Right arrow Articles by Perricone, C.
Related Collections
Right arrow Pregnancy and Rheumatic Diseases
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion: reply

R. Perricone1, C. De Carolis2, B. Kröegler1, E. Greco1, R. Giacomelli3, P. Cipriani3, L. Fontana4 and C. Perricone1

1Rheumatology, Department of Internal Medicine, University of Rome Tor Vergata, 2Department of Gynaecology and Obstetrics, S. Giacomo Hospital, ASL RMA, Rome, 3Rheumatology, Department of Internal Medicine, University of L'Aquila, L'Aquila and 4Internal Medicine, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy

Correspondence to: R. Perricone, Rheumatology, Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. E-mail: roberto.perricone@uniroma2.it

The first 10% of the full text of this article appears below.

The Letter to the Editor from Buyukhatipoglu et al [1] raises several interesting concerns regarding the high-dose Intravenous Immunoglobulin (IVIg) treatment in pregnant patients affected with SLE. Indeed, we agree when they state that rheumatologists have limited therapeutic options in SLE pregnancy due to complications in SLE itself, to the occurrence of recurrent spontaneous abortion (RSA) and to the small proportion of drugs that can be said to be safe in pregnancy. Therefore, in these patients the reported evidence on the use of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?